PPL 003

Drug Profile

PPL 003

Alternative Names: PPL-003

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Portage Biotech
  • Developer EyGen; Portage Biotech
  • Class Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes; Neurological disorders; Uveitis

Most Recent Events

  • 14 Dec 2016 Preclinical trials in Neurological disorders in USA (unspecified route)
  • 26 Apr 2015 Portage Pharmaceuticals announces intention to submit IND for PPL 003
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top